1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452

In development [GID-TA11557] Expected publication date: TBC

  • Project information
  • Project documents

31253-Darolutamide-Androgen-Deprivation-Therapy-for-Prostate-Cancer-V1.0-APR2024-NON-CONF.pdf (nihr.ac.uk)